What Would You Do?

A year and a half ago, Cordula Volkening’s doctors gave her a grim diagnosis: brain cancer. Still, having been told that she might have a year to live, she decided to embark on a career as a painter.



Ms. Volkening, a 52-year-old mother of two from Brooklyn, said she thinks of painting as a coping mechanism. Years ago, as an art student in Germany — before immigrating to Brooklyn and starting her own interior construction design business — she considered painting her passion. Now she finds that painting keeps her in the moment, instead of worrying about the future, or pining for her healthier past.



“I wanted to make the most of my remaining time; it’s keeping me sane,” said Ms. Volkening, whose speech has been impaired by her condition. “When I paint, it’s happy, it’s independent.”



She is painting not only for her state of mind, but also for the future of her two children, who live with Ms. Volkening’s former husband: her son, Skye, 16, an aspiring actor, and her daughter, Eden, 13. She finished 30 paintings in her first three months and went on to have three art shows in Brooklyn at which she sold thousands of dollars’ worth of her work, to leave to her children.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap